CAGE Bio Announces Positive Phase 2b Results in Atopic Dermatitis
CAGE Bio reported positive results from its Phase 2b trial of CGB-500 for atopic dermatitis (AD), a condition affecting more than 200 million people worldwide. The study enrolled 180 patients across 16 U.S. sites and met all primary and secondary endpoints, demonstrating strong treatment success, rapid itch relief, and a favorable safety profile.
CAGE Bio Announces Positive Phase 2b Results in Atopic Dermatitis